NCT02057263View on ClinicalTrials.gov

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Hepatitis B
Interventions
DRUG

Alendronate

Participants will receive 4 doses of alendronate during the course of the study.

DRUG

Hepatitis B Vaccine

Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.

DRUG

Placebo

Participants will receive 4 doses of placebo during the course of the study.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02057263 - The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter